CN1045293C - 取代的吡唑类化合物及含其的药物组合物 - Google Patents

取代的吡唑类化合物及含其的药物组合物 Download PDF

Info

Publication number
CN1045293C
CN1045293C CN93120122A CN93120122A CN1045293C CN 1045293 C CN1045293 C CN 1045293C CN 93120122 A CN93120122 A CN 93120122A CN 93120122 A CN93120122 A CN 93120122A CN 1045293 C CN1045293 C CN 1045293C
Authority
CN
China
Prior art keywords
alkyl
ylmethyl
methyl
compound
diethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93120122A
Other languages
English (en)
Chinese (zh)
Other versions
CN1093363A (zh
Inventor
G·M·布赖特
小·W·M·韦尔奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1093363A publication Critical patent/CN1093363A/zh
Application granted granted Critical
Publication of CN1045293C publication Critical patent/CN1045293C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN93120122A 1992-12-17 1993-12-16 取代的吡唑类化合物及含其的药物组合物 Expired - Fee Related CN1045293C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99222892A 1992-12-17 1992-12-17
US992,228 1992-12-17

Publications (2)

Publication Number Publication Date
CN1093363A CN1093363A (zh) 1994-10-12
CN1045293C true CN1045293C (zh) 1999-09-29

Family

ID=25538068

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93120122A Expired - Fee Related CN1045293C (zh) 1992-12-17 1993-12-16 取代的吡唑类化合物及含其的药物组合物

Country Status (26)

Country Link
EP (2) EP0959074A3 (https=)
JP (1) JP2781661B2 (https=)
KR (1) KR100190730B1 (https=)
CN (1) CN1045293C (https=)
AT (1) ATE187451T1 (https=)
AU (1) AU690079B2 (https=)
BR (1) BR9307664A (https=)
CA (1) CA2150703C (https=)
CZ (1) CZ287925B6 (https=)
DE (1) DE69327254T2 (https=)
DK (1) DK0674631T3 (https=)
EG (1) EG20440A (https=)
ES (1) ES2139676T3 (https=)
FI (1) FI111254B (https=)
GR (1) GR3032461T3 (https=)
HU (1) HUT65822A (https=)
IL (1) IL107947A (https=)
MY (1) MY109522A (https=)
NO (1) NO307884B1 (https=)
NZ (1) NZ256620A (https=)
PL (1) PL175982B1 (https=)
PT (1) PT674631E (https=)
RU (1) RU2130453C1 (https=)
TW (1) TW237455B (https=)
WO (1) WO1994013661A1 (https=)
ZA (1) ZA939406B (https=)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
BR9407799A (pt) 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
EP0738268B1 (en) * 1993-12-22 2004-03-03 Celltech R&D Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
FI964893A7 (fi) 1994-06-06 1996-12-05 Pfizer Substituoituja pyratsoleja, jotka ovat aktiivisia kortikotropiinin vap auttamistekijän (CRF) antagonisteina
AU719558B2 (en) * 1994-06-06 2000-05-11 Pfizer Inc. Substituted pyrazoles having corticotropin-releasing factor (CRF) antagonist activity
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US6011052A (en) * 1996-04-30 2000-01-04 Warner-Lambert Company Pyrazolone derivatives as MCP-1 antagonists
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US5861398A (en) * 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
US6159980A (en) * 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US5760225A (en) * 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
EP0946523A1 (en) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DK0976745T3 (da) 1997-03-26 2003-10-27 Taisho Pharmaceutical Co Ltd 4-tetrahydropyridylpyrimidinderivat
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
US5955471A (en) * 1998-01-13 1999-09-21 Sk Corporation Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
US6291473B1 (en) 1998-04-02 2001-09-18 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino [2, 3-B] indole and 5,6,7,8-tetrahydro-9H-pyrimidino [4, 5-B] indole derivatives: CRF1 specific ligands
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
ES2180338T3 (es) 1998-11-12 2003-02-01 Neurocrine Biosciences Inc Antagonistas del receptor de crf y metodos relacionados.
PT1129096E (pt) 1998-11-12 2003-09-30 Neurocrine Biosciences Inc Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6409988B1 (en) 1999-07-01 2002-06-25 3-Dimensional Pharmaceuticals, Inc. Radiolabeled 1-aryl pyrazoles, the synthesis thereof and the use thereof as pest GABA receptor ligands
US6506784B1 (en) 1999-07-01 2003-01-14 3-Dimensional Pharmaceuticals, Inc. Use of 1,3-substituted pyrazol-5-yl sulfonates as pesticides
WO2001007413A1 (en) * 1999-07-22 2001-02-01 3-Dimensional Pharmaceuticals, Inc. 1-aryl-3-thioalkyl pyrazoles, the synthesis thereof and the use thereof as insecticides
WO2001025241A2 (en) 1999-10-06 2001-04-12 3-Dimensional Pharmaceuticals, Inc. Fused 1-(2,6-dichloro-4-trifluoromethylphenyl)-pyrazoles, the synthesis thereof and the use thereof as pesticides
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
US6569885B1 (en) 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
AU2001232271A1 (en) * 2000-02-14 2001-08-20 Japan Tobacco Inc. Preventives/remedies for postoperative stress
AU2001234180A1 (en) * 2000-02-25 2001-09-03 Japan Tobacco Inc. Benzamide derivative and use thereof
GB0016453D0 (en) * 2000-07-04 2000-08-23 Hoffmann La Roche Pyrrole derivatives
GB0016787D0 (en) * 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
GB0024795D0 (en) * 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
US20060223824A1 (en) 2000-11-28 2006-10-05 Wyeth Serotonergic agents
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
HUP0401292A3 (en) 2001-04-27 2011-01-28 Eisai R & D Man Co Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
BR0209774A (pt) 2001-05-29 2004-06-01 Schering Ag Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
WO2003026649A1 (en) * 2001-09-27 2003-04-03 Applied Research Systems Ars Holding N.V. Methods of increasing endogenous testosterone levels
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
TWI283679B (en) 2002-10-22 2007-07-11 Eisai Co Ltd 7-phenylpyrazolopyridine compounds
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
NZ540591A (en) 2002-12-13 2008-03-28 Warner Lambert Co Pregabalin derivatives for the treatment of fibromyalgia and other disorders
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
CA2632021A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
BRPI0714440A2 (pt) * 2006-07-21 2013-04-24 Irm Llc composto inibidor de itpkb, uso do mesmo e composiÇço farmacÊutica
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
JP2010529993A (ja) 2007-06-15 2010-09-02 アイアールエム・リミテッド・ライアビリティ・カンパニー ＩＴＰＫｂ阻害剤としての化合物および組成物
CA2716080C (en) 2008-02-20 2016-12-13 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
EP2266990B1 (en) 2008-04-15 2012-09-26 Eisai R&D Management Co., Ltd. 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUND
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
DE102013002393A1 (de) 2013-02-13 2014-08-14 Rauch Landmaschinenfabrik Gmbh Verfahren zur Regelung des Massenstromes an Streugut bei einem Scheibenstreuer
CN114716389A (zh) * 2021-12-31 2022-07-08 北京岳达生物科技有限公司 一种3,5-二乙基异恶唑-4-羧酸的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1427781A1 (ru) * 1987-02-13 1992-04-23 Научно-исследовательский институт фармакологии АМН СССР 4-Аминокарбонил- или 4-аминоэтил-5-метилпиразолы, обладающие способностью регулировать скорость выведени этанола

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds

Also Published As

Publication number Publication date
FI111254B (fi) 2003-06-30
CZ287925B6 (cs) 2001-03-14
TW237455B (https=) 1995-01-01
GR3032461T3 (en) 2000-05-31
ATE187451T1 (de) 1999-12-15
EP0959074A2 (en) 1999-11-24
HUT65822A (en) 1994-07-28
AU690079B2 (en) 1998-04-23
ES2139676T3 (es) 2000-02-16
IL107947A0 (en) 1994-04-12
CA2150703C (en) 2002-01-08
NZ256620A (en) 1996-05-28
ZA939406B (en) 1995-06-15
NO952397D0 (no) 1995-06-16
PL175982B1 (pl) 1999-03-31
EP0674631B1 (en) 1999-12-08
PT674631E (pt) 2000-04-28
WO1994013661A1 (en) 1994-06-23
JPH08500121A (ja) 1996-01-09
CN1093363A (zh) 1994-10-12
EG20440A (en) 1999-04-29
AU5141393A (en) 1994-07-04
BR9307664A (pt) 1999-06-29
PL309355A1 (en) 1995-10-02
DE69327254T2 (de) 2000-03-30
NO307884B1 (no) 2000-06-13
CA2150703A1 (en) 1994-06-23
EP0674631A1 (en) 1995-10-04
CZ158295A3 (en) 1995-12-13
JP2781661B2 (ja) 1998-07-30
MY109522A (en) 1997-02-28
EP0959074A3 (en) 2000-06-07
KR950704299A (ko) 1995-11-17
NO952397L (no) 1995-08-14
FI935672L (fi) 1994-06-18
DE69327254D1 (de) 2000-01-13
IL107947A (en) 1998-08-16
RU2130453C1 (ru) 1999-05-20
KR100190730B1 (ko) 1999-06-01
FI935672A0 (fi) 1993-12-16
DK0674631T3 (da) 2000-04-10

Similar Documents

Publication Publication Date Title
CN1045293C (zh) 取代的吡唑类化合物及含其的药物组合物
CN106008322B (zh) 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物
RU2142946C1 (ru) Производные пиразола и фармацевтическая композиция, содержащая их
CN1215061C (zh) 制备抗癌化合物的方法和中间体
CN1097054C (zh) 三环类吡唑衍生物及其组合物
CN1219131A (zh) 作为tnf抑制剂和pdc－iv抑制剂的喹啉甲酰胺类化合物
CN1922181A (zh) 通过使用咪唑并[1,2－b]哒嗪衍生物控制动物中的寄生虫
CN1149870A (zh) 具有促皮质激素释放因子拮抗剂活性的取代的吡唑
CN1534023A (zh) 作为多巴胺－d3配位体的杂环化合物
CN1314904A (zh) 用作抗癌剂的炔基取代的喹啉－2－酮衍生物
CS228532B2 (en) Production method of phenylpiperazine derivative
CN1100773C (zh) 苯并呋喃羧酸胺和磺酰胺
CN1133840A (zh) 吲哚哌啶衍生物
CN85101761A (zh) 新型色胺衍生物的制备方法和应用
CN1126473A (zh) 化学组合物
EP0677042B1 (fr) Ligands selectifs des recepteurs 5ht1d-5ht1b derives d'indole-piperazine utiles comme medicaments
CN1025854C (zh) 喹啉基噁唑-2-酮类化合物的制备方法
CN1049660C (zh) 苯并吡喃化合物，它们的制备方法和含有它们的药物组合物
CN1147485C (zh) 用作5-ht-2c受体拮抗剂的二氢吲哚衍生物
WO1995001334A1 (fr) Composes indoliques derives d'arylamines comme ligands selectifs des recepteurs 5ht1d et 5ht¿1b?
CN1452614A (zh) 芳基哌嗪衍生物及其作为精神药物的用途
CN1251571A (zh) 2－苯氧基苯胺类衍生物
CN1432013A (zh) 咪唑衍生物或其盐以及含有该衍生物或其盐的药物
CN1930124A (zh) 制备交叉偶联吲哚的方法
CN1411457A (zh) 取代的吡咯类化合物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee